Correlation analysis of soluble mediators in peripheral blood also established that increased levels of markers of myeloid cell dysregulation and many proinflammatory cytokines such as IL-1β and IL-18 were key features of VEXAS syndrome physiopathology, confirming the potential interest of targeted therapies against these markers (IL-1β, IL1-RA, IL6 and IL-18). Here, IL18 is linked to VEXAS syndrome.